Indications and uses
Treats excessive perspiration and reduces underarm wetness and odor.
Treats excessive perspiration and reduces underarm wetness and odor.
Apply to underarms only. Use every other night or as needed (e.g. every night or every 3rd nights). Apply only at bedtime. Apply few strokes to underarms after tipping bottle to get maximum effect.
Keep at room temperature
Aluminum Chloride Hexahydrate 12%
Antiperspirant
Treats excessive perspiration and reduces underarm wetness and odor.
For external use only
on irritated skin.
If swallowed, get medical help or contact a Poison Control Center right away
if rash or irritation develops
before using if you have kidney disease
Apply to underarms only. Use every other night or as needed (e.g. every night or every 3rd nights). Apply only at bedtime. Apply few strokes to underarms after tipping bottle to get maximum effect.
Water, PPG-11 Stearyl Ether, Cyclopentasiloxane, Steareth-2, Glycine, Steareth-20, Zinc Oxide, Sodium Bicarbonate, Isopropyl Myristate, Steareth-21
Keep at room temperature
clinical strength Miracle Dry ANTIPERSPIRANT DEODORANT PM NIGHT formula 1.2 FL OZ 35.5 ML
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 0ca1d589-929b-4b33-bc5b-1d84abdafa6a | Product name | 1 | 20150324 |
| fc363c46-397b-4476-ac0f-70e43e8e4592 | Product name | 1 | 20150324 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 53897-001-01 | Clinical Strength MiracleDry Antiperspirant Deodorant PM | 35.5 mL in 1 BOTTLE | LIQUID | 35.5 | 8 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 53897-001 | CLINICAL STRENGTH MIRACLEDRY ANTIPERSPIRANT DEODORANT PM (ALUMINUM CHLORIDE) LIQUID [HIGHLAND CONSUMER PRODUCTS] | 8 | Current NDC, Legacy NDC, 1 package rows | 20231213_f8f12e81-517b-4297-a61d-2e6daec53496.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ALUMINUM CHLORIDE | ACTIVE INGREDIENT | 3CYT62D3GA | 2 | |
| ALUMINUM CATION | ACTIVE MOIETY | 3XHB1D032B | 2 | |
| CYCLOMETHICONE 5 | INACTIVE INGREDIENT | 0THT5PCI0R | 2 | |
| GLYCINE | INACTIVE INGREDIENT | TE7660XO1C | 2 | |
| ISOPROPYL MYRISTATE | INACTIVE INGREDIENT | 0RE8K4LNJS | 2 | |
| PPG-11 STEARYL ETHER | INACTIVE INGREDIENT | S4G2J0Y0LG | 2 | |
| SODIUM BICARBONATE | INACTIVE INGREDIENT | 8MDF5V39QO | 2 | |
| STEARETH-2 | INACTIVE INGREDIENT | V56DFE46J5 | 2 | |
| STEARETH-20 | INACTIVE INGREDIENT | L0Q8IK9E08 | 2 | |
| STEARETH-21 | INACTIVE INGREDIENT | 53J3F32P58 | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 | |
| ZINC OXIDE | INACTIVE INGREDIENT | SOI2LOH54Z | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 53897-001 | 53897-001-01 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| WATER | 059QF0KO0R | IACT |
| PPG-11 STEARYL ETHER | S4G2J0Y0LG | IACT |
| CYCLOMETHICONE 5 | 0THT5PCI0R | IACT |
| STEARETH-2 | V56DFE46J5 | IACT |
| GLYCINE | TE7660XO1C | IACT |
| STEARETH-20 | L0Q8IK9E08 | IACT |
| ZINC OXIDE | SOI2LOH54Z | IACT |
| SODIUM BICARBONATE | 8MDF5V39QO | IACT |
| ISOPROPYL MYRISTATE | 0RE8K4LNJS | IACT |
| STEARETH-21 | 53J3F32P58 | IACT |
| ALUMINUM CHLORIDE | 3CYT62D3GA | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCINE | GLYCINE | TE7660XO1C | INJECTION / INTRAVENOUS | 200 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION / SUBCUTANEOUS | ADJ PH | ||
| CYCLOMETHICONE 5 | CYCLOMETHICONE 5 | 0THT5PCI0R | AEROSOL, FOAM / TOPICAL | 144 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | AEROSOL, FOAM / TOPICAL | 144 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | AEROSOL, FOAM / TOPICAL | 144 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, FOR SOLUTION / INTRAPERITONEAL | ADJ PH | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, SOLUTION / INTRAVENOUS | 52 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | CAPSULE / ORAL | 320 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, EFFERVESCENT / ORAL | 57600 mg | ||
| GLYCINE | GLYCINE | TE7660XO1C | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 200 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | FILM, SOLUBLE / ORAL | 2 mg | ||
| GLYCINE | GLYCINE | TE7660XO1C | INJECTION / INTRAVENOUS | 200 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 3219 mg | ||
| GLYCINE | GLYCINE | TE7660XO1C | CAPSULE, DELAYED RELEASE / ORAL | 50 mg | ||
| STEARETH-20 | STEARETH-20 | L0Q8IK9E08 | CREAM / TOPICAL | 4.15 %w/w | ||
| GLYCINE | GLYCINE | TE7660XO1C | POWDER, FOR SUSPENSION / ORAL | 400 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | OIL / TOPICAL | 213 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 6 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | GEL / TOPICAL | 29 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION / INTRAMUSCULAR | 175 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | INSERT / VAGINAL | 129 mg | ||
| GLYCINE | GLYCINE | TE7660XO1C | TABLET, CHEWABLE / ORAL | 267 mg | ||
| GLYCINE | GLYCINE | TE7660XO1C | TABLET, ORALLY DISINTEGRATING / ORAL | 60 mg | ||
| CYCLOMETHICONE 5 | CYCLOMETHICONE 5 | 0THT5PCI0R | AEROSOL / TOPICAL | 2.5 %w/w | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, COATED / ORAL | 10.6 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, FILM COATED / ORAL | 86 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | LOZENGE / ORAL | 100 mg | ||
| ZINC OXIDE | ZINC OXIDE | SOI2LOH54Z | LOTION / TOPICAL | 16 %w/w | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION / INTRAMUSCULAR | 175 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | SOLUTION / ORAL | ADJ PH | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | LOTION / TOPICAL | 50 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | GUM, CHEWING / BUCCAL | 240 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET / ORAL | 1300 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | GUM, CHEWING / BUCCAL | 240 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | GUM, CHEWING / ORAL | 360 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION / INTRATHECAL | 0.05 mg | ||
| GLYCINE | GLYCINE | TE7660XO1C | INJECTION / INTRAMUSCULAR | 68 mg | ||
| STEARETH-2 | STEARETH-2 | V56DFE46J5 | LOTION / TOPICAL | 0.4 %w/w | ||
| PPG-11 STEARYL ETHER | POLYPROPYLENE GLYCOL 11 STEARYL ETHER | S4G2J0Y0LG | SUSPENSION / TOPICAL | 2288 mg | ||
| GLYCINE | GLYCINE | TE7660XO1C | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 0.38 %w/v | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | INSERT / VAGINAL | 129 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET / BUCCAL | 42 mg | ||
| GLYCINE | GLYCINE | TE7660XO1C | CAPSULE, DELAYED RELEASE / ORAL | 50 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | ADJ PH | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, EXTENDED RELEASE / ORAL | 81 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | FILM, SOLUBLE / ORAL | 2 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | SOLUTION / RESPIRATORY (INHALATION) | 2 %w/w | ||
| STEARETH-2 | STEARETH-2 | V56DFE46J5 | OINTMENT / TOPICAL | 714 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | LOZENGE / ORAL | 100 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 3219 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, CHEWABLE / ORAL | 140 mg | ||
| GLYCINE | GLYCINE | TE7660XO1C | TABLET / ORAL | 163.31 mg | ||
| CYCLOMETHICONE 5 | CYCLOMETHICONE 5 | 0THT5PCI0R | CREAM, AUGMENTED / TOPICAL | 260 mg | ||
| GLYCINE | GLYCINE | TE7660XO1C | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 40 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | CAPSULE / ORAL | 320 mg | ||
| CYCLOMETHICONE 5 | CYCLOMETHICONE 5 | 0THT5PCI0R | AEROSOL, FOAM / TOPICAL | 144 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET / ORAL | 1300 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | OIL / TOPICAL | 213 mg | ||
| GLYCINE | GLYCINE | TE7660XO1C | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 200 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | SPRAY / TOPICAL | 3665 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Clinical Strength MiracleDry Antiperspirant Deodorant PM | ALUMINUM CHLORIDE | Highland Consumer Products | f8f12e81-517b-4297-a61d-2e6daec53496 | 2023-12-12 | Warnings | 53897-001-01 53897-001 53897000101 0c5b6a69-0a65-0f46-e063-6294a90a4fca f8f12e81-517b-4297-a61d-2e6daec53496 |
Adverse event summaries are temporarily unavailable. Other product information remains available.